CN106333366A - Composition with anti-fatigue effect and preparation method and application thereof - Google Patents
Composition with anti-fatigue effect and preparation method and application thereof Download PDFInfo
- Publication number
- CN106333366A CN106333366A CN201610859051.9A CN201610859051A CN106333366A CN 106333366 A CN106333366 A CN 106333366A CN 201610859051 A CN201610859051 A CN 201610859051A CN 106333366 A CN106333366 A CN 106333366A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- composition
- preparation
- taurine
- glucose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 79
- 238000002360 preparation method Methods 0.000 title claims abstract description 38
- 230000000694 effects Effects 0.000 title claims abstract description 36
- 230000002929 anti-fatigue Effects 0.000 title claims abstract description 33
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 60
- 244000068988 Glycine max Species 0.000 claims abstract description 30
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 30
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 30
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 30
- 229960003080 taurine Drugs 0.000 claims abstract description 30
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 25
- 239000002994 raw material Substances 0.000 claims abstract description 22
- 239000008103 glucose Substances 0.000 claims abstract description 19
- 240000008397 Ganoderma lucidum Species 0.000 claims abstract description 9
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 5
- 235000013305 food Nutrition 0.000 claims abstract description 4
- 239000000843 powder Substances 0.000 claims description 35
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 20
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 239000012467 final product Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 241000222336 Ganoderma Species 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 8
- 239000000047 product Substances 0.000 claims description 6
- 230000003750 conditioning effect Effects 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- 239000004376 Sucralose Substances 0.000 claims description 4
- 235000015165 citric acid Nutrition 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 235000019634 flavors Nutrition 0.000 claims description 4
- 229960001031 glucose Drugs 0.000 claims description 4
- 235000019202 steviosides Nutrition 0.000 claims description 4
- 235000019408 sucralose Nutrition 0.000 claims description 4
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 4
- 108010011485 Aspartame Proteins 0.000 claims description 3
- 229930091371 Fructose Natural products 0.000 claims description 3
- 239000005715 Fructose Substances 0.000 claims description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
- 239000004383 Steviol glycoside Substances 0.000 claims description 3
- 239000000605 aspartame Substances 0.000 claims description 3
- 235000010357 aspartame Nutrition 0.000 claims description 3
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 3
- 229960003438 aspartame Drugs 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 235000019411 steviol glycoside Nutrition 0.000 claims description 3
- 229930182488 steviol glycoside Natural products 0.000 claims description 3
- 150000008144 steviol glycosides Chemical class 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims description 2
- 241000206575 Chondrus crispus Species 0.000 claims description 2
- 239000001879 Curdlan Substances 0.000 claims description 2
- 229920002558 Curdlan Polymers 0.000 claims description 2
- 229920002148 Gellan gum Polymers 0.000 claims description 2
- 229920002752 Konjac Polymers 0.000 claims description 2
- 240000000111 Saccharum officinarum Species 0.000 claims description 2
- 235000007201 Saccharum officinarum Nutrition 0.000 claims description 2
- 235000010358 acesulfame potassium Nutrition 0.000 claims description 2
- 229960004998 acesulfame potassium Drugs 0.000 claims description 2
- 239000000619 acesulfame-K Substances 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 235000013361 beverage Nutrition 0.000 claims description 2
- 235000015895 biscuits Nutrition 0.000 claims description 2
- 235000012970 cakes Nutrition 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 235000019316 curdlan Nutrition 0.000 claims description 2
- 229940078035 curdlan Drugs 0.000 claims description 2
- 235000013312 flour Nutrition 0.000 claims description 2
- 229960002737 fructose Drugs 0.000 claims description 2
- 239000000216 gellan gum Substances 0.000 claims description 2
- 235000010492 gellan gum Nutrition 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 229920001277 pectin Polymers 0.000 claims description 2
- 239000001814 pectin Substances 0.000 claims description 2
- 235000010987 pectin Nutrition 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000001509 sodium citrate Substances 0.000 claims description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 2
- 235000011083 sodium citrates Nutrition 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims 1
- 238000000227 grinding Methods 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract 1
- 229940056905 magnesium l-threonate Drugs 0.000 abstract 1
- YVJOHOWNFPQSPP-BALCVSAKSA-L magnesium;(2r,3s)-2,3,4-trihydroxybutanoate Chemical compound [Mg+2].OC[C@H](O)[C@@H](O)C([O-])=O.OC[C@H](O)[C@@H](O)C([O-])=O YVJOHOWNFPQSPP-BALCVSAKSA-L 0.000 abstract 1
- 230000009182 swimming Effects 0.000 description 8
- 241000219095 Vitis Species 0.000 description 5
- 235000009754 Vitis X bourquina Nutrition 0.000 description 5
- 235000012333 Vitis X labruscana Nutrition 0.000 description 5
- 235000014787 Vitis vinifera Nutrition 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- CNNRPFQICPFDPO-UHFFFAOYSA-N octacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCO CNNRPFQICPFDPO-UHFFFAOYSA-N 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 229960002666 1-octacosanol Drugs 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 240000005373 Panax quinquefolius Species 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010065369 Burnout syndrome Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 229910003978 SiClx Inorganic materials 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- LXIUJOQXHQOBSX-UHFFFAOYSA-N acetic acid chloroethene Chemical compound ClC=C.ClC=C.CC(O)=O LXIUJOQXHQOBSX-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the field of medicines, health-care products or food, and particularly relates to an anti-fatigue composition and a preparation method and application thereof. The composition comprises the following raw materials in parts by weight: 1-13 parts of magnesium L-threonate, 0.1-8 parts of taurine, 1-24 parts of glucose, 0.1-11 parts of soybean oligopeptide and 0.1-10 parts of ganoderma lucidum spore. The composition with the anti-fatigue effect takes full account of the raw materials, and selects proportions among the raw materials, so that the raw materials cooperate with one another in accordance with the proportions and act together to play the anti-fatigue effect; the composition is simple in raw materials and relatively low in cost; the composition can be prepared by grinding and uniformly mixing; the preparation method is relatively simple and convenient.
Description
Technical field
The invention belongs to medicine, health products or field of food and in particular to a kind of composition with antifatigue effect and
Its preparation method and purposes.
Background technology
Fatigue is a comprehensive physiology course being related to many Physiology and biochemistry factors, is that human body is mental or physical exertion
A kind of normal physiological phenomenon necessarily occurring during to certain phase, had both indicated the temporary transient decline of the original ability to work of body,
Possibly body develops into a tendency of sick and wounded state again.When human body is chronically under fatigue state, can produce prematurely senile
And burnout syndrome, excessive fatigue even can accelerate death.Human body feels fatigue although unlike the oncoming force such as cancer, heart disease are fast
Suddenly, directly and promptly cause death, but it, as a kind of stealthy killer of harm modern's health, has had a strong impact on people
Work and life, considerably increase sub-health population quantity.
Chinese patent literature cn104585732a discloses a kind of Reishi sporule health food, includes by weight percentage
Following component: Ganoderma spore extract 20-30%, American Ginseng 66-78% and n-octacosanol 2-4% composition；Preparation glossy ganoderma spore
The method of sub- health food: (1), by Reishi sporule ultramicro grinding, de-oiling, water extraction, filtration, a. filtrate concentrate drying is ground into spirit
Ganoderma lucidum spore extract fine powder, or the concentration of b. filtrate, alcohol precipitation, take precipitation to be dried and crushed into Ganoderma spore extract fine powder；(2) the West
Ginseng is cleaned, is dried, sterilizing, is ground into fine powder；(3) n-octacosanol is ground into fine powder；(4) each fine powder above is mixed
Grain, packing, quality inspection is qualified, obtains final product；It has preferable physical fatigue of alleviating and acts on.However, there is cost relatively in above-mentioned composition
The shortcomings of height, preparation method are more complicated, thus limit its application.
Therefore, the new therapeutic effect of research is good, toxic and side effect is little, cost is relatively low, preparation method is easier have anti-
The medicine of fatigue effect or health products are significant.
Content of the invention
Therefore, the present invention provides the tool that a kind of therapeutic effect is good, toxic and side effect is little, cost is relatively low, preparation method is easier
There is the composition of antifatigue effect, and then its preparation method and purposes are provided.
For solving above-mentioned technical problem, the present invention is achieved through the following technical solutions:
The present invention provides a kind of composition with antifatigue effect, and the raw material of described composition includes:
L- magnesium threonate 1～13 weight portion, taurine 0.1～8 weight portion, glucose 1～24 weight portion, soybean oligopeptide
0.1～11 weight portion, lucidum spore powder 0.1～10 weight portion.
Preferably, the above-mentioned composition with antifatigue effect of the present invention, the raw material of described composition includes:
L- magnesium threonate 4～10 weight portion, taurine 2～6 weight portion, glucose 6～18 weight portion, soybean oligopeptide 3
～8 weight portions, lucidum spore powder 2～8 weight portion.
It is further preferred that the above-mentioned composition with antifatigue effect of the present invention, the raw material of described composition includes:
L- magnesium threonate 7 weight portion, taurine 4 weight portion, glucose 12 weight portion, soybean oligopeptide 5 weight portion, glossy ganoderma
Conidia powder 5 weight portion；Or
L- magnesium threonate 4 weight portion, taurine 6 weight portion, glucose 6 weight portion, soybean oligopeptide 8 weight portion, glossy ganoderma
Conidia powder 2 weight portion；Or
L- magnesium threonate 10 weight portion, taurine 2 weight portion, glucose 18 weight portion, soybean oligopeptide 3 weight portion, spirit
Ganoderma lucidum spore powder 8 weight portion；Or
L- magnesium threonate 6 weight portion, taurine 5 weight portion, glucose 9 weight portion, soybean oligopeptide 3 weight portion, glossy ganoderma
Conidia powder 4 weight portion；Or
L- magnesium threonate 5 weight portion, taurine 3 weight portion, glucose 8 weight portion, soybean oligopeptide 5 weight portion, glossy ganoderma
Conidia powder 6 weight portion.
It is further preferred that the above-mentioned composition with antifatigue effect of the present invention, the raw material of described composition also includes:
Local flavor conditioning agent 0.1～3 weight portion,
Described local flavor conditioning agent is selected from citric acid, malic acid, sodium citrate, Sucralose, fructose, acesulfame potassium, stevioside
At least one in glycosides, sucrose, Aspartame, konjaku flour, xanthans, carragheen, curdlan, gellan gum, pectin.
The present invention also provides a kind of preceding claim to have the preparation method of the composition of antifatigue effect, including following
Step:
Take l- magnesium threonate, taurine, glucose, soybean oligopeptide and the lucidum spore powder of selected weight portion respectively, grind
Grind, mix, obtain final product.
The present invention also provides a kind of preparation method of the above-mentioned composition with antifatigue effect, comprises the following steps:
Take l- magnesium threonate, taurine, glucose, soybean oligopeptide, lucidum spore powder and the wind of selected weight portion respectively
Taste conditioning agent, grinds, mixes, obtain final product.
The present invention also provides preparation or the above-mentioned preparation method of inclusion including the above-mentioned composition with antifatigue effect
The preparation of the composition preparing,
Described composition adds customary adjuvant, according to common process, make clinically acceptable tablet, capsule, dissipate
Agent, mixture, pill, granule, solution, syrup, soft extract, beverage, biscuit, candy or cake.
Described customary adjuvant is: filler, disintegrant, lubricant, suspending agent, adhesive, sweetener, flavouring, anti-corrosion
Agent, matrix etc..Filler includes: starch, pregelatinized starch, lactose, mannitol, chitin, microcrystalline cellulose, sucrose etc.；Collapse
Solution agent includes: starch, pregelatinized starch, microcrystalline cellulose, sodium carboxymethyl starch, PVPP, low replacement hydroxyl
Third cellulose, cross-linked carboxymethyl cellulose are received；Lubricant includes: magnesium stearate, lauryl sodium sulfate, talcum powder, dioxy
SiClx etc.；Suspending agent includes: polyvinylpyrrolidone, microcrystalline cellulose, sucrose, agar, hydroxypropyl methyl cellulose etc.；Bonding
Agent includes, starch slurry, polyvinylpyrrolidone, hydroxypropyl methyl cellulose etc.；Sweetener includes: saccharin sodium, aspartame, sugarcane
Sugar, honey element, enoxolone etc.；Flavouring includes: sweetener and various essence；Preservative includes: parabens, benzoic acid,
Sodium Benzoate, sorbic acid and its esters, benzalkonium bromide, the fixed, eucalyptus oil of acetic acid chloroethene etc.；Matrix includes: peg6000,
Peg4000, insect wax etc..
The present invention also provides the composition preparing including above-mentioned composition, above-mentioned preparation method or above-mentioned composition
Preparation preparation there is antifatigue effect medicine, health products or food in application.
Technical scheme has the advantage that
(1) present invention has the composition of antifatigue effect, takes into full account each raw material l- magnesium threonate, taurine, grape
The composition of sugar, soybean oligopeptide and lucidum spore powder, and select each raw material proportioning each other, make each raw material according to its proportioning
Cooperate, collective effect, thus playing antifatigue effect；
(2) present invention has the composition of antifatigue effect, and composition is simple, cost is relatively low；
(3) pass through to grind, mix and can be prepared by composition of the present invention, preparation method is easier.
Specific embodiment
In following examples of the present invention and experimental example, all raw materials are commercially available product.
Embodiment 1
The raw material that the present embodiment has the composition of antifatigue effect consists of: l- magnesium threonate 7g, taurine 4g, grape
Sugared 12g, soybean oligopeptide 5g, lucidum spore powder 5g；
The preparation method of said composition, comprises the following steps: takes the l- magnesium threonate of selected weight, taurine, Portugal respectively
Grape sugar, soybean oligopeptide and lucidum spore powder, grind, mix, obtain final product.
The composition that the present embodiment has antifatigue effect adds customary adjuvant, according to common process, makes granule.
Embodiment 2
The raw material that the present embodiment has the composition of antifatigue effect consists of: l- magnesium threonate 4g, taurine 6g, grape
Sugared 6g, soybean oligopeptide 8g, lucidum spore powder 2g, citric acid 0.1g；
The preparation method of said composition, comprises the following steps: takes the l- magnesium threonate of selected weight, taurine, Portugal respectively
Grape sugar, soybean oligopeptide, lucidum spore powder and citric acid, grind, mix, obtain final product.
The composition that the present embodiment has antifatigue effect adds customary adjuvant, according to common process, makes capsule.
Embodiment 3
The raw material that the present embodiment has the composition of antifatigue effect consists of: l- magnesium threonate 10g, taurine 2g, Portugal
Grape sugar 18g, soybean oligopeptide 3g, lucidum spore powder 8g, Sucralose 0.8g；
The preparation method of said composition, comprises the following steps: takes the l- magnesium threonate of selected weight, taurine, Portugal respectively
Grape sugar, soybean oligopeptide, lucidum spore powder and Sucralose, grind, mix, obtain final product.
The composition that the present embodiment has antifatigue effect adds customary adjuvant, according to common process, makes syrup.
Embodiment 4
The raw material that the present embodiment has the composition of antifatigue effect consists of: l- magnesium threonate 6g, taurine 5g, grape
Sugared 9g, soybean oligopeptide 3g, lucidum spore powder 4g, fructose 1.0g；
The preparation method of said composition, comprises the following steps: takes the l- magnesium threonate of selected weight, taurine, Portugal respectively
Grape sugar, soybean oligopeptide and lucidum spore powder, grind, mix, obtain final product.
The composition that the present embodiment has antifatigue effect adds customary adjuvant, according to common process, makes solution.
Embodiment 5
The raw material that the present embodiment has the composition of antifatigue effect consists of: l- magnesium threonate 5g, taurine 3g, grape
Sugared 8g, soybean oligopeptide 5g, lucidum spore powder 6g, steviol glycoside 3g；
The preparation method of said composition, comprises the following steps: takes the l- magnesium threonate of selected weight, taurine, Portugal respectively
Grape sugar, soybean oligopeptide, lucidum spore powder and steviol glycoside, grind, mix, obtain final product.
The composition that the present embodiment has antifatigue effect adds customary adjuvant, according to common process, makes tablet.
Experimental example 1The research of present composition antifatigue effect
1st, experiment purpose
The antifatigue effect of the research present composition.
2nd, experiment material
Respectively with embodiment 1 preparation composition, embodiment 2 preparation composition, embodiment 3 preparation composition as confession
Test product.
3rd, experimental technique
Take 80 of the same age, 20～25g healthy mices, male and female half and half.It is randomly divided into 4 groups, every group 20, male and female half and half,
It is respectively 1 group of experimental group, 2 groups of experimental group, 3 groups of experimental group and blank control group.
1,2,3 groups of experimental group gavages the composition 10g/kg/ day of embodiment 1,2,3 preparation respectively, and one time a day；Blank right
Gavage 2.0ml physiological saline 1 time according to group, one time a day；Continue 28.
From gavaging the 6th, each group animal daily 25 DEG C～30 DEG C deep water middle reaches soak 3.5 hours as stress, continue 4
Week.
Mouse is put in deep water, voluntarily swims, its nose, eye, the crown and ears are all exposed at the water surface, two metapedes are struck, straight line
Swimming, shows that power is contained；As two metapedes struck slow or do not draw, the water surface covers ears, the submergence crown, shows that power declines, and certainly enters water extremely
Time for declining is the animal movement endurance time.
During swimming test, observe its swimming state, the time changing, judge its endurance.
4th, experimental result
Stress be after 4 weeks, the measured endurance time be as shown in table 1 for each group mouse.
The impact to the Tolerance of Swimming time for the table 1
As shown in Table 1, (1), compared with blank control group, the swimming endurance time that 1,2 and 3 groups of experimental group all extends；
(2) compared with 2 groups of experimental group or 3 groups of experimental group, the swimming endurance time lengthening of 1 group of experimental group is more notable.
This shows, the composition of present invention preparation can be remarkably reinforced Tolerance of Swimming, has antifatigue effect；Embodiment
The composition of 1 preparation more can be remarkably reinforced Tolerance of Swimming, and antifatigue effect is more notable.
Obviously, above-described embodiment is only intended to clearly illustrate example, and the not restriction to embodiment.Right
For those of ordinary skill in the art, can also make on the basis of the above description other multi-forms change or
Change.There is no need to be exhaustive to all of embodiment.And the obvious change thus extended out or
Change among still in the protection domain of the invention.
Claims (8)
1. a kind of composition is it is characterised in that the raw material of described composition includes:
L- magnesium threonate 1～13 weight portion, taurine 0.1～8 weight portion, glucose 1～24 weight portion, soybean oligopeptide 0.1
～11 weight portions, lucidum spore powder 0.1～10 weight portion.
2. composition according to claim 1 is it is characterised in that the raw material of described composition includes:
L- magnesium threonate 4～10 weight portion, taurine 2～6 weight portion, glucose 6～18 weight portion, soybean oligopeptide 3～8 weight
Amount part, lucidum spore powder 2～8 weight portion.
3. composition according to claim 2 is it is characterised in that the raw material of described composition includes:
L- magnesium threonate 7 weight portion, taurine 4 weight portion, glucose 12 weight portion, soybean oligopeptide 5 weight portion, Reishi sporule
Powder 5 weight portion；Or
L- magnesium threonate 4 weight portion, taurine 6 weight portion, glucose 6 weight portion, soybean oligopeptide 8 weight portion, Reishi sporule
Powder 2 weight portion；Or
L- magnesium threonate 10 weight portion, taurine 2 weight portion, glucose 18 weight portion, soybean oligopeptide 3 weight portion, glossy ganoderma spore
Sub- powder 8 weight portion；Or
L- magnesium threonate 6 weight portion, taurine 5 weight portion, glucose 9 weight portion, soybean oligopeptide 3 weight portion, Reishi sporule
Powder 4 weight portion；Or
L- magnesium threonate 5 weight portion, taurine 3 weight portion, glucose 8 weight portion, soybean oligopeptide 5 weight portion, Reishi sporule
Powder 6 weight portion.
4. the composition according to any one of claim 1-3 is it is characterised in that the raw material of described composition also includes: wind
Taste conditioning agent 0.1～3 weight portion,
Described local flavor conditioning agent is selected from citric acid, malic acid, sodium citrate, Sucralose, fructose, acesulfame potassium, steviol glycoside, sugarcane
At least one in sugar, Aspartame, konjaku flour, xanthans, carragheen, curdlan, gellan gum, pectin.
5. a kind of preparation method of the composition described in any one of claim 1-3 is it is characterised in that comprise the following steps:
Take l- magnesium threonate, taurine, glucose, soybean oligopeptide and the lucidum spore powder of selected weight portion respectively, grind, mix
Close uniformly, obtain final product.
6. a kind of preparation method of the composition described in claim 4 is it is characterised in that comprise the following steps:
The l- magnesium threonate, taurine, glucose, soybean oligopeptide, lucidum spore powder and the local flavor that take selected weight portion respectively are adjusted
Section agent, grinds, mixes, obtain final product.
7. include the preparation of composition described in any one of claim 1-4 or include the preparation described in claim 5 or 6
The preparation of the composition that method prepares it is characterised in that
Described composition adds customary adjuvant, according to common process, makes clinically acceptable tablet, capsule, powder, conjunction
Agent, pill, granule, solution, syrup, soft extract, beverage, biscuit, candy or cake.
8. the combination that the composition described in any one of claim 1-4, the preparation method described in claim 5 or 6 prepare
The preparation of the composition described in thing or claim 7 answering in medicine, health products or the food that preparation has antifatigue effect
With.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610859051.9A CN106333366A (en) | 2016-09-28 | 2016-09-28 | Composition with anti-fatigue effect and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610859051.9A CN106333366A (en) | 2016-09-28 | 2016-09-28 | Composition with anti-fatigue effect and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106333366A true CN106333366A (en) | 2017-01-18 |
Family
ID=57840451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610859051.9A Pending CN106333366A (en) | 2016-09-28 | 2016-09-28 | Composition with anti-fatigue effect and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106333366A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1357323A (en) * | 2001-12-26 | 2002-07-10 | 北京巨能亚太生命科学研究中心 | New application of threonic acid and its salt |
| CN104883911A (en) * | 2013-01-11 | 2015-09-02 | Mjn美国控股有限责任公司 | Nutritional compositions containing magnesium threonate and uses thereof |
| CN105142648A (en) * | 2013-03-15 | 2015-12-09 | 玛格塞蒂克斯公司 | Magnesium compositions and uses thereof for cancers |
| CN105682654A (en) * | 2013-10-14 | 2016-06-15 | 雅培公司 | Compositions and methods for improving cognitive function |
| CN105685960A (en) * | 2016-02-16 | 2016-06-22 | 江苏隆力奇生物科技股份有限公司 | Composition with refreshing and anti-fatigue effects, method for preparing composition and application thereof |
-
2016
- 2016-09-28 CN CN201610859051.9A patent/CN106333366A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1357323A (en) * | 2001-12-26 | 2002-07-10 | 北京巨能亚太生命科学研究中心 | New application of threonic acid and its salt |
| CN104883911A (en) * | 2013-01-11 | 2015-09-02 | Mjn美国控股有限责任公司 | Nutritional compositions containing magnesium threonate and uses thereof |
| CN105142648A (en) * | 2013-03-15 | 2015-12-09 | 玛格塞蒂克斯公司 | Magnesium compositions and uses thereof for cancers |
| CN105682654A (en) * | 2013-10-14 | 2016-06-15 | 雅培公司 | Compositions and methods for improving cognitive function |
| CN105685960A (en) * | 2016-02-16 | 2016-06-22 | 江苏隆力奇生物科技股份有限公司 | Composition with refreshing and anti-fatigue effects, method for preparing composition and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11033566B2 (en) | Method of improving lacrimal secretion for dry eye treatment using maqui berry extract | |
| DE69633502T2 (en) | PROCYANIDINE AS THE ACTIVE INGREDIENT AGAINST GRAVITY | |
| CN101810285A (en) | Hawthorn food with function of improving eyesight and preparation method thereof | |
| DE60215866T2 (en) | MEDICAMENT CONTAINING CYANIDINE-3-GLYCOSIDE AS AN ACTIVE AGENT AGAINST FAT SUPPORT AND DIABETES | |
| CN106236739A (en) | Compositions containing phylloxanthin/lutein ester and application thereof | |
| CN107205459A (en) | Composition | |
| CN105685960A (en) | Composition with refreshing and anti-fatigue effects, method for preparing composition and application thereof | |
| KR101760512B1 (en) | Compositions comprising mixed herbal extracts for preventing, treating or improving chronic inflammatory diseases | |
| JP2006187258A (en) | IMMUNE STRENGTH AMELIORATING FOOD CONTAINING beta-GLUCAN DERIVED FROM BAKER'S YEAST | |
| JP5071618B2 (en) | Exocrine gland dysfunction improving agent and foods | |
| CN109363009A (en) | A kind of Radix Astragali blueberry composition and Radix Astragali blueberry drink prepared therefrom and preparation method thereof | |
| CN106999532A (en) | The enhancing of Motor execution ability and physical enhancement composition containing composite extract | |
| JP2006306804A (en) | Wrinkle formation inhibitor | |
| JP2004035510A (en) | Composition for prophylaxis or treatment of diabetes mellitus or its complication | |
| KR20130077317A (en) | Functional food composition for improving skin condition and preparation method thereof | |
| CN106333366A (en) | Composition with anti-fatigue effect and preparation method and application thereof | |
| JP2005139135A (en) | Prophylactic and ameliorating agent of menopausal disorder | |
| JP2005089374A (en) | Food and drink having function for preventing increase in blood glucose level | |
| KR20190066460A (en) | Pharmaceutical composition comprising the seed extracts of rambutan as an effective component for prevention or treatment of diabetes and health functional food comprising the same | |
| WO2005074961A1 (en) | Body fat-controlling agent | |
| JP2003002831A (en) | Ameliorating agent for female hormone abnormality disorder | |
| KR101221621B1 (en) | Food composition for fatigue recovery or stress suppression comprising extract of reed-root | |
| JP2012031132A (en) | Composition for ameliorating fatigue | |
| KR101151339B1 (en) | Food composition for fatigue recovery or stress suppression comprising extract of reed-root, chinesequince and rice bran | |
| JP2005022994A (en) | Hypoglycemic composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170118 |
|
| RJ01 | Rejection of invention patent application after publication |